Evidence map›Paper›PMID 30047070›Full record

ArticleDrugs & aging2018

Safety of Antidepressant Classes Used Following Traumatic Brain Injury Among Medicare Beneficiaries: A Retrospective Cohort Study.

Jennifer S Albrecht, Vani Rao, Eleanor M Perfetto, C Daniel Mullins

Open access · greenAbstract readComparative Study
In one paragraph

Article in Drugs & aging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 4 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 4 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds.European psychiatry : the journal of the Association of European Psychiatrists · 2024
    Pooled it
  4. Stroke risk following traumatic brain injury: Systematic review and meta-analysis.International journal of stroke : official journal of the International Stroke Society · 2021
    Pooled it
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jennifer S AlbrechtDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, MSTF 334C, 10 S. Pine St., Baltimore, MD, 21201, USA. jalbrecht@epi.umaryland.edu.ORCID http://orcid.org/0000-0003-4838-2274
Vani RaoDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Eleanor M PerfettoDepartment of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA.
C Daniel MullinsDepartment of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA.
University of Maryland, Baltimore · USJohns Hopkins University · US

Funding

Prioritizing Quality Improvement for the Treatment of Psychiatric Disturbances Following Traumatic Brain InjuryK01HS024560 · AHRQ · UNIVERSITY OF MARYLAND BALTIMORE · PI ALBRECHT, JENNIFER S. · 2016 to 2020
$735k
Agency for Healthcare Research and Quality K01HS024560AHRQ HHS K01 HS024560U.S. Department of Defense W81XWH-13-1-0469
6 · The paper itself

Abstract

objectiveThere is poor evidence supporting the use of any pharmacologic treatments for neuropsychiatric disorders following traumatic brain injury (TBI), especially among older adults. Informed by our recent characterization of psychotropic medication use among Medicare beneficiaries with TBI, the objective of this study was to compare the risk of several adverse events associated with use of the three most commonly used classes of antidepressants following TBI in this population.

methodsWe conducted a retrospective cohort study using administrative claims data from US Medicare beneficiaries hospitalized with TBI between 2006 and 2010 (n = 30,886). We assessed monthly selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), and tricyclic antidepressant (TCA) use. We identified adverse events associated with these drug classes that were available in administrative claims data from studies in TBI and non-TBI populations: seizures, hemorrhagic stroke, ischemic stroke, gastrointestinal bleed, hyponatremia, and fractures. We made comparisons between antidepressant classes to assess excess risk of each adverse event using discrete time analysis and controlling for potential confounders.

resultsSSRIs were the most commonly used of the antidepressant classes, followed by SNRIs and TCAs. We observed a total of 23,021 adverse events. Ischemic stroke was the most frequent (8296 events). Hemorrhagic stroke (1706 events) and seizures (1841) were least often observed. Compared with TCAs, SSRI use was associated with an increased risk of hemorrhagic stroke (risk ratio 2.47; 95% confidence interval 1.30-4.70). No other antidepressant class comparisons were associated with increased risk of adverse events.

conclusionCompared with SSRIs, use of SNRIs and TCAs following hospitalization for TBI among Medicare beneficiaries was not associated with an increased risk of any of the studied adverse events. Compared to TCAs, SSRI use was associated with increased risk of hemorrhagic stroke. This information may help guide patients and prescribers in selecting antidepressants for older adults following TBI.

Indexed as

HospitalizationAgedAged, 80 and overAntidepressive AgentsBrain Injuries, TraumaticFemaleFractures, BoneHumansMaleMedicareRetrospective StudiesRiskSeizuresSelective Serotonin Reuptake InhibitorsStrokeUnited StatesAntidepressive AgentsSelective Serotonin Reuptake Inhibitors

Identifiers

PMID30047070
PMCPMC12744690
OpenAlexW2884185582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.